spacer
Adler Graduate School Practical Psychology Inspiring Change

"The chief danger in life is that you may take too many precautions."
--Alfred Adler

School Overview Admissions Academics Tuition & Financial Aid Workshops Student Services Contact Us Home
Adler Classroom spacer AGS News
spacer Bookstore spacer Library spacer AGS News spacer resources spacer open house schedule  
spacer
Current Newsletter

Announcements Board

Newsletter Sign-Up

Newsletter Archives (PDF)

2006
January
February
March
April
May
June
July
August
September
October
November
December

2005
January
February
March
April
May
June
July
August
September
October
November
December

2004
February
April
June
July
August
September
October
November
December

 
6
MAMFT-Minnesota Association for Marriage & Family Therapy MAMFT offers a variety of programs throughout the year. Check out their website at http://www.minnesotafamilies.org/ for details.
MN Jung Association The Minnesota Jung Association has a variety of lectures and presentations scheduled. Events take place in Stubb Hall at Luther Seminary in St. Paul. For a calendar of their events click here.
NASAP NASAP (North American Society of Adlerian Psychology) has a variety of listings for presentations and training.
TAPTalk
Professional Development
MN Psychoanalytic Society The Minnesota Psychoanalytic Society (Freudians) have a variety of events listed for 2007-2008. Check out their calendar at http://www.mpsi.info/plugins/calendar_menu/event.php.
Suicide Prevention Resource Center (SPRC) The Weekly Spark provides news about Suicide and its prevention from National (US), State and International sources and also has links to articles about Research and Funding Opportunities. The link to the current news can be found here. Their archives of article links are located here.
Kenwood Center Workshops For information about Kenwood Center Narative Therapy Workshops click here.
U of M Center for Austrian Studies

Those interested in the cultural milieu in which Adler, Freud, Jung, et al, developed their theories may want to check out events at the U of M Center for Austrian Studies at http://www.cas.umn.edu/calendar/.
Their Lecture Series does not appear to be on their calendar at present:

U of M Humphrey Institute The Humphrey Institute of Public Affairs at the the University of Minnesota offers a variety of lectures and presentations which may be of interest. You can check their calendar of events here.
U of M Events
(General Listing)
A listing of all events happening at the University of Minnesota can be found at http://events.umn.edu/. It is organized by day but can be viewed by month and then day.
Wed. Feb. 17, 2010
Issues in Mental Health Nursing via Ken Pope

Antipsychotic medications and cardiac conduction risks" by Marian Roman & Shirley Farmer -- appears in the journal *Issues in Mental Health Nursing* (vol. 31, #1).

Here's the abstract:

[begin abstract]

Many non-cardiac medications as well as non-medicinal substances (caffeine to cocaine) can affect cardiac conduction. Time and continued research have revealed that both first and second generation antipsychotics (as well as antidepressants) can effect a prolonged QTc interval on electrocardiogram (ECG), denoting a conduction change that sets the stage for serious arrhythmias.

This article reviews the effects of antipsychotic medications on cardiac conduction.

Topics covered include cardiac conduction as depicted on ECG, Torsades de Pointes (an arrhythmia that has been induced by some antipsychotic medications), and the effects of comorbid conditions on developing potentially fatal arrhythmias.

Guidelines are provided for the prudent prescribing of antipsychotic medications.

[end abstract]

The author note provides the following contact info: Marian Roman, University of Tennessee-Knoxville, School of Nursing, 1200 Volunteer Boulevard, Knoxville, TN, US, 37996, <mroman@utk.edu>.

Wed. Feb. 17, 2010
Psychiatric Times via Ken Pope

"Opening Pandora's Box: The 19 Worst Suggestions For DSM5" by Allen Frances, MD.

The author note states: "Dr Frances was the chair of the DSM-IV TaskForce and of the department of psychiatry at Duke University School of Medicine, Durham, NC. He is currently professor emeritus at Duke. "Here are some excerpts:

[begin excerpts]I have previously criticized the DSM5 process--for its unnecessary secretiveness, its risky ambitions, its disorganized methods, and its unrealistic deadlines. Now, it is finally time to evaluate the first draft ... Poor and inconsistent writing. Perhaps it should occasion no surprise that a flawed process should yield a flawed product. The most fundamental problem is the poor and inconsistent writing.

<snip>Higher rates of mental disorder In terms of content, most concerning are the many suggestions for DSM5 that would dramatically raise the rates of mental disorder.

<snip>DSM5 would create tens of millions of newly misidentified false positive "patients," thus greatly exacerbating the problems caused already by an overly inclusive DSM4. There would be massive overtreatment with medications that are unnecessary, expensive, and often quite harmful. DSM5 appears to be promoting what we have most feared--the inclusion of many normal variants under the rubric of mental illness, with the result that the core concept of "mental disorder" is greatly undermined. Unforeseen consequences: A third pervasive weakness in the DSM5 options is their insensitivity to possible misuse in forensic settings.

<snip>PROBLEMATIC NEW DIAGNOSES: The Psychosis Risk Syndrome is certainly the most worrisome of all thesuggestions made for DSM5. The false positive rate would be alarming--70% to 75% in the most careful studies and likely to be much higher once the diagnosis is official, in general use, and becomes a target for drug companies. Hundreds of thousands of teenagers and young adults (especially, it turns out, those on Medicaid) would receive the unnecessary prescription of atypical antipsychotic drugs. There is no proof that the atypical antipsychotics prevent psychotic episodes, but they do most certainly cause large and rapid weight gains (see the recent FDA warning) and are associated with reduced life expectancy--to say nothing about their high cost, other side effects, and stigma.

<snip>Mixed Anxiety Depressive Disorder taps nonspecific symptoms that are widely distributed in the general population and would therefore immediately become one of the most common of all the mental disorders in DSM5.

<snip>Minor Neurocognitive Disorder is defined by nonspecific symptoms of reduced cognitive performance that are very common (perhaps almost ubiquitous) in people over fifty. To protect against false positives, there is a criterion that requires objective cognitive assessment to confirm that the individual has decreased cognitive performance, but getting a meaningful reference point is impossible in most instances and the threshold has been set to include a whopping 13.5% of the population (ie, the percent of population within the first and second standard deviation). Moreover, the suggestion for objective testing will probably be widely ignored in the primary care settings where the bulk of diagnosing will be done.

<snip>Binge Eating Disorder will have a rate in the general population (estimated at 6%) and this will probably become much higher when the diagnosis becomes popular and is made in primary care settings.

<snip>Temper Dysfunctional Disorder with Dysphoria is one of the most dangerous and poorly conceived suggestions for DSM5--a misguided medicalization of temper outbursts.

<snip>The misapplication of this diagnosis would provide a blanket excuse for reduced personal responsibility and will lead to forensic nightmares. It is a nonstarter. Paraphilic Coercive Disorder would expand the pool of sex offenders who are eligible for indefinite civil commitment because they have a "mental disorder" to include cases of sexual coercion. Paraphilic Coercive Disorder was initially considered for inclusion in DSM-III-R (under the name Paraphilic Rapism) but was rejected because it was impossible to reliably and validly differentiate those rapists whose actions are the result of a paraphilia from the large majority of rapists who are motivated by other factors (such as power).

<snip>Hypersexuality Disorder would be a gift to false positive excuse seekers and potential forensic disaster. Another clear nonstarter. A Behavioral Addictions category would be included with the substance addictions section and would start life with one disorder, Pathological Gambling (transferred from Impulse Disorders section). Next in line might be a new category for Internet Addiction. This could provide a slippery slope leading to the back door inclusion of a variety of silly and potentially harmful diagnoses (ie,"addictions" to shopping, sex, work, credit card debt, videogames etc,etc, etc) under the broad rubric of "behavioral addictions not otherwise specified." The construct "Behavioral Addictions" represents a medicalization of life choices, provides a ready excuse for off loading personal responsibility, and would likely be misused in forensic settings.

LOWERED THRESHOLDS: The greatest general impact would come from the suggestion to eliminate the "clinical significance" criterion required in DSM4 for each disorder that has a fuzzy boundary with normality (about two-thirds of them). These were included to ensure the presence of clinically significant distress or impairment when the symptoms of the disorder in mild form might be compatible with normality. Removing this requirement would reduce the role of clinical judgment as a gatekeeper in determining the presence or absence of mental disorders and thus would increase the already swollen rates of psychiatric diagnosis.

Attention Deficit/Hyperactivity Disorder. The DSM4 wording changes (along with extremely active drug company marketing) contributed to escalating rates of ADD - accompanied by the widespread misuse of stimulant medications for performance enhancement and the emergence of a large secondary illegal market. There are 4 suggestions for DSM5 that would make this existing overdiagnosis much worse.*The first change is to raise the required age of onset from 7 to 12. The second is to allow the diagnosis based only on the presence of symptoms, not requiring impairment. The third is to reduce by half the number of symptoms required for adults. These 3 changes greatly reduce the specificity of the ADD diagnosis in adolescents and adults and will result in a further flood of false positives and of resulting stimulus misuse for performance enhancement. The fourth change is to allow the diagnosis of ADD in the presence of autism. This might create the interaction of 2 false epidemics, encouraging increased stimulant use in an especially vulnerable population.

Addiction Disorder. DSM5 proposes to eliminate the distinction between substance abuse and substance dependence, lowering the threshold for diagnosing the new unified category-- "addiction"--that would be introduced to replace them both.

<snip>Autism Spectrum Disorder. Asperger's disorder would be collapsed into this new unified category. Although this consolidation appeals to some experts, it remains controversial and presents serious problems. Those with Asperger's (which is much less impairing) will be stigmatized by the association with classic autistic disorder. Moreover, in the average everyday practice conducted by non-experts, the spectrum concept will likely further fuel the "epidemic" of loosely defined autism that was already been triggered by the introduction of Asperger's in DSM4.

Medicalizing Normal Grief. DSM5 would reverse 30 years of diagnostic practice and allow the diagnosis of Major Depression to be made for individuals whose grief reaction symptomatically resembles a Major Depressive episode (eg, 2 weeks of depressed mood, loss of interest inactivities, insomnia, loss of appetite, and trouble concentrating immediately following the loss of a spouse would be a mental disorder.

<snip>Pedohebephilia is one of the most poorly written and unworkable of the suggested criteria sets.

<snip>Deleting the Multiaxial System. This would result in the loss of much valuable clinical information. Multi-axial diagnosis provides a disciplined approach to distinguishing between state and trait (Axis I versus Axis II) and to determining the contributions of medical conditions (Axis I II) and of stressors (Axis IV) to the diagnosis and treatment of psychiatric disorders. The GAF score (Axis V) provides the most convenient and familiar rating of overall functioning. No compelling rationale is offered for making so radical a change.

Various Small Changes. There are numerous small editorial changes meant to help clarify the existing criteria sets. Some of these appear to be improvements, many are trivial, and some are worse than their DSM4 counterparts. Any possible gain from wording changes has to be weighed against the risks that the new version will create its own set of unanticipated consequences.

<snip>Dimensional Assessments: Three dimensional assessments (for severity, co-morbid symptoms, and personality traits) are suggested for DSM5. Dimensions are most appropriate in describing continuously distributed phenomena that can be reduced to numbers. It has been widely accepted for several decades that adding dimensions would help to solve the categorical system's problem with fuzzy boundaries- thus improving the accuracy and precision of psychiatricdiagnosis. Unfortunately, however, the field has never achieved consensus on which dimensions to choose and how best to measure them. Moreover, and most crucial, clinicians find dimensional ratings far too unfamilar and cumbersome for use in everyday practice and all efforts to include even a few simple dimensional ratings into previous DSM's have been met by clinician resistance and neglect. The DSM5 dimensional proposals are especially problematic--ad hoc,unworkably complex, vague, untested, and premature.

<snip>Severity ratings tailored for each disorder. In fact, this approach was tried for 8 categories in DSM3R, but was dropped in DSM4 because the anchors of the severity ratings were not validated and the system was too cumbersome for routine clinical use.

<snip>Ratings on "crosscutting" symptoms that exist across a number ofdifferent diagnoses to supplement the primary categorical diagnosis. Such assessment might be useful in some settings, but is far too cumbersome for use in routine clinical practice.

Dimensional ratings for personality. These would, in theory, have clear advantages over the clumsy categorical approach to personality assessment. In practice, however, the multiple, complicated, confusing, and cumbersome systems suggested for DSM5 would be far too unfamiliar and time consuming to ever be used by clinicians. Another side effect would be deletion of five of the personality disorders (paranoid, narcissistic, histrionic, dependent, schizoid) from the manual.

CONCLUSIONS: It will likely be argued by the DSM5 leadership that I am unduly and prematurely alarmist, that they are still early in the DSM5 process, and that any problematic suggestions will eventually be weeded out in the field trials. This is putting the cart (ie field testing) before the horse (ie having usable criteria sets to test) and continues to miss the point that DSM5 has been and remains in serious trouble. I feel it is my responsibility to raise clear alarms now because the past performance of the DSM5 leadership does not inspire confidence in its future ability to avoid serious mistakes. What leads me to this pessimistic conclusion? Every step in the development of DSM5 has been secretive and disorganized. The leadership has established a consistent track record of proposing unrealistic plans and impossible to meet timetables--with predictably erratic course changes and repeatedly missed deadlines. It was, for example, announced last May at the APA annual meeting (and in the press) that the DSM5 field trials were about to begin in the summer of 2009. Then, it turned out that none of the necessary preparatory steps had been accomplished and the field trials had to be postponed for at least a year.

<snip>I wish to emphasize that the problems in this DSM5 draft are not at all the fault of the Work Group members who have labored hard under very unpromising conditions. The DSM5 options are poorly conceived and executed because of the interaction of 4 unfortunate decisions made by the DSM5 leadership:
1. Requiring unnecessary confidentiality agreements that insulated the Work Groups from the usual and necessary corrective interaction with the field
2. Tightly restricting Advisors to a small and highly selected group
3. Establishing the expectation that Work Groups be innovative rather than risk/benefit conscious
4. Providing the Work Groups with remarkably little guidance,consistency, and editorial assistance. Because of the secretive and closed nature of the DSM5 process, the expectable enthusiasms of the experts who comprise the Work Groups have not been balanced, as they must always be, with real world practical clinical wisdom and a careful risk/benefit analysis of the possible unintended consequences of every suggestion.

<snip>What needs to be done next? The responsibility (and opportunity) for rescuing DSM5 falls most heavily on the field at large and on the Oversight Committee. Now that the DSM5 drafts are finally open for wide review, it behooves the field to be active in identifying problems and providing the needed pressure to ensure they will be corrected. My recommendations for the Oversight Committee are:
1. Extend the period allotted for public review to 3 months.
2. Use this time to ensure the careful editing of each word of each item of every criteria set to provide the clarity and consistency that is nowsorely lacking and is absolutely necessary before any meaningful field testing can begin.
3. Post field trial methods for public review.
4. Appoint 3 subcommittees reporting to the Oversight Committee(responsible, respectively, for monitoring forensic review, risk benefit analysis, and field trials.
5. Post the literature reviews and plans for ICD-11 harmonization. Every future step in the preparation of DSM5 should involve active interaction with the field and with the Oversight Committee and its subcommittees. Unnecessary secrecy has caused the current problems and only full transparency and openness to outside input will solve them. I have had the space and expertise to identify only the DSM5 troublespots that are most obvious to me. The rest is up to you.  Please take the time to review the DSM5 options (at least in your areasof interest) and supply your input. They can be found at www.dsm5.org.

[end excerpts]

The article is online at:<http://bit.ly/9DHv6L>

Wed. Feb. 10, 2010
American Psychiatric Association

Here are the "Proposed Draft Revisions to DSM Disorders and Criteria": http://www.dsm5.org/Pages/Default.aspx

Thu. Jan. 14, 2010
Current Psychiatry Online

January 2010 ONLINE NOW

Borderline, bipolar, or both?
Frame your diagnosis on the patient history

Careful attention to conceptual distinctions may reduce the risk
of misdiagnosis.

1 WEB AUDIO
Borderline or bipolar? Don't skimp on the life story

Jess G. Fiedorowicz, MD, explains why a thorough and rigorous psychiatric history is essential to distinguish these 2 disorders.

Thu. Jan. 7, 2010
University of St. Thomas

St. Thomas, Graduate School of Professional Psychology, is seeking an MFT adjunct faculty member for the 2010-2011 year. The position would require leading the 12-month practicum class sequence for MFT students, beginning June 2010 and ending May 2011. This is a seminar class (max of 8 students) that is typically held on Wednesday evenings (4:30-7:30pm).  The class meets weekly to discuss clinical issues & professional development. Students are expected to read texts, submit work samples for review, complete formal case presentations, & submit a formal person, theory, practice paper.  Courses that make up the practicum sequence include: CPSY608, CPSY 609, CPSY 610 and CPSY 655 for a total of 12 credits.

The ideal candidate must hold a doctoral degree, be an approved supervisor with the MN Board of Marriage and Family Therapy, and have experience providing clinical supervision to MFT students/ practitioners. St. Thomas offers a competitive adjunct salary, extensive support (orientation, office space, training in the use of classroom technology, & monthly practicum supervisors meetings), and all classes are held on the downtown Minneapolis campus.

Interested parties are asked to send a CV and letter of interest to:

Susan E. Andersson, PsyD, MA, LMFT
Director of Evaluation & Practica
University of St. Thomas
Graduate School of Professional Psychology
Office: MOH 445 J
Mail:    MOH 217
1000 LaSalle Avenue
Minneapolis, MN 55403
(651) 962-4641 (phone)
(651) 962-4651 (fax)

Tue. July 28, 2009

Subject: Fwd: Darkness Linked to Depressed People's Cognitive Impairment

A colleague sent this out. The flaw in studies like this is that they don't measure someone's actual exposure to sunlight.
Many depressed people don't go outside a lot so how much sunlight is out there does not tell you who
is taking advantage of it.

Gary

Subject: Darkness Linked to Depressed People's Cognitive Impairment

The journal *Environmental Health* issued the following news release:

Under a cloud -- darkness linked to 'brain drain' in depressed people.

A lack of sunlight is associated with reduced cognitive function amongdepressed people.

Researchers writing in BioMed Central's journal Environmental Healthused weather data from NASA satellites to measure sunlight exposureacross the United States and linked this information to the prevalenceof cognitive impairment in depressed people.

Shia Kent, from the University of Alabama at Birmingham, led a team ofUS researchers who used cross-sectional data from 14,474 people in theNIH-NINDS-funded REGARDS study, a longitudinal study investigatingstroke incidence and risk factors, to study associations betweendepression, cognitive function and sunlight.

He said, "We found that among participants with depression, low exposureto sunlight was associated with a significantly higher predictedprobability of cognitive impairment.

This relationship remained significant after adjustment for season.

This new finding that weather may not only affect mood, but alsocognition, has significant implications for the treatment of depression,particularly seasonal affective disorder".

Kent and his colleagues speculate that the physiological mechanisms thatgive rise to seasonal depression may also be involved in sunlight'seffect on cognitive function in the context of depressive symptoms.Cognitive function was assessed by measurement of short-term recall andtemporal orientation.

As well as regulating the hormones serotonin and melatonin, light hasbeen shown to also affect brain blood flow, which has in turn beenlinked with cognitive functions. The researchers write, "Discovering the environment's impact oncognitive functioning within the context of seasonal disorders may leadnot only to better understanding of the disorders, but also to thedevelopment of targeted interventions to enhance everyday functioningand quality of life".

Ken Pope

RESOURCES FOR THOSE LOOKING FOR NURSING HOMES OR HOSPICES, OR WHO AREFACING END-OF-LIFE CHALLENGES:<http://kspope.com/hospices/index.php>

Tue. July 14, 2009
Minnesota Food Helpline

On June 1st, Hunger Solutions Minnesota launched the Minnesota Food Helpline, a toll-free, statewide food resource information and referral helpline.  Callers can be screened for Food Support (formerly Food Stamps) eligibility and assisted with completing the application for Food Support.  We can also assist callers in locating food resources in their own community whether it be a food shelf and/or hot meal site.  In addition, we make referrals for other public food programs like20WIC (Women, Infants and Children), MAC (Mothers and Children) and NAPS (Nutrition Assistance Program for Seniors).

Here's why the Minnesota Food Helpline is so necessary in our community:

The Number of People in Need of Food Continues to Grow - 

Visits to food shelves in the nine-county Metro Area increased 42% year to date in February. On average, food shelves statewide report a 31% increase in usage.

Food Support/Food Stamp Benefits Can Help Feed Families - 

Food Support provides low income families at risk for hunger with more choices, less stigma, self sufficiency and more consumer power.

  • The state of Minnesota estimates that only 68% of those that are eligible for Food Support are participating in the program.
  • Approximately 80% of eligible seniors are not enrolled due to a variety of barriers and misconceptions about eligibility.
  • According to the U.S. Department of Agriculture, $5 in new Food Support benefits generates $9.20 in total community spending.

We want to be a resource to all Minnesotans including those at risk of experiencing hunger and the professionals that work with them.  I’m wondering if it’s possible for you to include information about the Minnesota Food Helpline on your website and/or in your next communication to those you serve or your membership.  Materials such as posters and business cards are also available for on-site promotion.

Minnesota Food Helpline - a program of Hunger Solutions Minnesota

8:30-4:30 - Monday through Friday

Multilingual phone assistance is available

1-888-711-1151

At the Minnesota Food Helpline, we work with callers to find both short and long-term solutions. No one in Minnesota should go hungry.  Please contact me with any questions.  I look forward to hearing from you.  Thanks.

Cathy Patterson

Member Services Manager

Hu nger Solutions Minnesota

651-789-9844/800-782-6372 ext. 844

The Minnesota Food Helpline - a program of Hunger Solutions Minnesota

We help put food within reach of those in need.

1-888-711-1151

Mon. June 16, 2009
APA, et al.

APA et al.: Joint Statement on Atypical Antipsychotic Use in Kids; stats, recommendations

Subject: APA et al.: Joint Statement on Atypical Antipsychotic Use in Kids; stats, recommendations

A "Joint Statement on Atypical Antipsychotic Use in Children" has been issued by:

American Academy of Child and Adolescent Psychiatry - www.aacap.org

American Foundation for Suicide Prevention - www.afsp.org

American Psychiatric Association - www.psych.org

Child and Adolescent Bipolar Foundation - www.bpkids.org

Children and Adults with Attention-Deficit/Hyperactivity Disorder - www.chadd.org

Families for Depression Awareness - www.familyaware.org

Mental Health America - www.mentalhealthamerica.net

National Alliance on Mental Illness - www.nami.org

National Council for Community Behavioral Healthcare - www.TheNationalCouncil.org

JOINT STATEMENT ON ATYPICAL ANTIPSYCHOTIC USE IN CHILDREN

As advocates for people living with mental illnesses, we strongly urge the FDA to carefully consider the importance of viable treatment options for bipolar disorder and schizophrenia in pediatric and adolescent populations.

Access to safe and effective treatments, including more information about all treatment options, is crucial to treating these serious and complex conditions in children and adolescents.

Bipolar disorder and schizophrenia are very real, life-threatening diseases which can appear in childhood and adolescence. For example, federally funded research (STEP-BD) found that, of 3,658 adult patients studied, 68% reported bipolar disease onset in childhood or adolescence.

Patients with child onset had, on average, fewer days of euthymia (or neutral mood), greater impairment in functioning and poorer quality of life.

Those with adolescent onset have better outcomes than those with child onset, but were still worse off than those who did not suffer from bipolar disorder until adulthood.

These alarming statistics highlight the need for early recognition and treatment, which offers children and adolescents their best chance to achieve and maintain wellness.

We encourage an open and transparent scientific discourse about all pharmacologic treatments that come before the Advisory Committee and urge the Committee to carefully weigh the available evidence regarding safety and efficacy.

No one treatment option works for all children. In order for physicians and families to make informed treatment decisions they need access to a full range of medications and treatment options and to the research regarding the risks and benefits of these treatments.

More long-term clinical research in children and adolescents is also needed to better understand the risks and benefits of these medications when used over an extended period.

As we know, these medications can also have serious side effects, which is why it is crucial that parents and physicians have as much information as possible in order to make informed decisions and weigh the risk of side effects and adverse reactions against the risk of not treating these very serious diseases.

Other treatments for grave childhood illnesses such as cancer can cause hair loss, nausea, compromised immune systems and even death.

However, few people question the necessity of these aggressive forms of treatment.

Like cancer, aggressive treatment may be needed for some patients with bipolar disorder and schizophrenia, diseases with a higher risk of death than some forms of cancer.

The best way to protect the health of our nation's children and adolescents is to increase access to treatment options and communicate accurate, scientific information that helps parents and physicians cope with and properly treat these devastating illnesses.

Our non-profit national mental health advocacy and medical professional organizations represent consumers, physicians, researchers and the top experts in the field of mental health and neuroscience.

For more information about mental illness and treatment, we recommend that you talk to your health care provider or visit our organization websites.

Thu. May 7, 2009

Psychologist Kenneth Pope sent this out.

Subject: Lexapro vs. Zoloft vs. other antidepressants

The Cochrane Database issued the following news release:

Newer Antidepressants Not Always Better

New antidepressants might be no more effective than the best existing drugs, according to two new systematic reviews that compared 12 commonly used medications.

"Patients are usually encouraged to take the newest medication," said lead author Andrea Cipriani, M.D., of the University of Verona, in Italy. "But it's better to have an old treatment that has been proved with many patients and many years in the market."

The reviews suggest that sertraline -- sold under the brand name Zoloft since 1991-- could be the best initial choice of antidepressant in people with acute major depression.

The generic formulation produced the best balance of effectiveness, tolerability and purchase price, the authors say.

Patients also did well on one of the newest antidepressants, escitalopram (Lexapro), but it is not yet available in lower-cost generic form. The authors note that comprehensive economic studies are necessary to evaluate overall cost-effectiveness of various treatments.

Cipriani said that the review recommendations are for new episodes of depression. "If a patient is taking another drug and doing well, we are not saying he has to change."

The reviews appear in the most recent issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Depression is the fourth-leading cause of disease burden worldwide and antidepressant drugs are now the mainstay of treatment for moderate to severe cases. The aim of the two reviews was to compare the benefits and side effects of sertraline and escitalopram, respectively, with those of other antidepressants during the first six to 12 weeks of treatment.

Cipriani noted that all of the included studies compared one drug against another -- not to a placebo -- so the results reveal not the absolute effect, but rather the relative advantages and disadvantages of various medications.

In addition, these reviews rely on summary data from each study, rather than individual patient data. Future studies that go into greater detail can help identify the best medications for various subgroups of patients such as men vs. women, teens vs. adults and so on.

For sertraline, the reviewers included 59 randomized controlled trials totaling about 10,000 participants. Sertraline proved more effective than fluoxetine (Prozac), but less effective than mirtazapine (Remeron). In terms of side effects, bupropion (Wellbutrin) was easier to tolerate than sertraline, while the latter outscored amitriptyline (Elavil), imipramine (Tofranil), paroxetine (Paxil) and mirtazapine (Remeron).

For escitalopram, the reviewers included 22 randomized controlled trials totaling about 4,000 participants. Few statistically significant differences appeared in this review, although escitalopram was more effective than citalopram (Celexa) and fluoxetine (Prozac) and had fewer side effects than duloxetine (Cymbalta). The drug manufacturer sponsored most of the studies in this review, so there may be biases in favor of escitalopram.

Rather than seeking genuine advances in treatment, the review authors say, some pharmaceutical companies seem to be introducing close chemical cousins of generic medications. By gaining patent protection for the "new" drug, a company can market it as a higher-priced brand name product.

Sponsorship bias is a recurring concern in trials of virtually all new medications. In the Cochrane reviews themselves, one of the co-authors has received research funds and speaking fees from the companies Asahi Kasei, Astellas, Dai-Nippon Sumitomo, Eisai, Eli Lilly, GlaxoSmithKline, Janssen, Kyowa Hakko, Meiji, Nikken Kagaku, Organon, Otsuka, Pfizer and Yoshitomi. The Japanese Ministry of Education, Science and Technology, and the Japanese Ministry of Health, Labour and Welfare have also funded some of his research.

However, the co-authors of these Cochrane reviews also published a recent study in The Lancet that was free of any potential funding bias. The study also used a more complex statistical method to analyze data from 117 randomized controlled trials involving 25,928 participants.

The findings support the Cochrane reviews, Cipriani said, with sertraline and escitalopram ranking as the best treatments.

"Such findings have enormous implications," said Sagar Parikh, M.D., of the University of Toronto, in a commentary published along with The Lancet study. "For the clinician, prudent engagement of the patient in treatment ideally involves giving the patient a choice.... A new gold standard of reliable information has been compiled for patients to review."

In early studies, new medical treatments are typically compared to sham treatments. Once the effectiveness of certain approaches is well established, new options must be judged against the best existing treatments.

Cipriani argued that this time has come for antidepressants, and that sertraline is the drug to beat. "We need new treatments in psychiatry, but they have to be proved better than other treatments," he said. "We should be comparing new drugs to the best available existing drugs."

The Cochrane Collaboration is an international nonprofit, independent organization that produces and disseminates systematic reviews of health care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions. Visit http://www.cochrane.org for more information.

Cipriani A, La Ferla, et al. Setraline versus other antidepressive agents for depression. The Cochrane Database of Systematic Reviews 2009, Issue 2.

Cipriani A, Santilli C, et al. Escitalopram versus other antidepressive agents for depression. The Cochrane Database of Systematic Reviews 2009, Issue 2.

Ken Pope

Tue. May 5, 2009
Kenwood Center

Narrative Therapy Certificate program

Program Description
Completely new, revised and updated,
the Kenwood Center Training
Institute offers a Narrative Therapy Certificate Program providing training with leading Narrative therapists Walter Bera, PhD, John Stillman, LICSW, author/therapist William Madsen, PhD, and John Windslade,. This advanced clinical training program runs from September to May. Those who complete the program will have the foundational
knowledge to work with individuals, couples, families and communities creatively, effectively and ethically across a wide range of problems.
The Certificate Program generally consists of monthly Friday workshops, small group training, texts, readings, research, and written assignments. The program is open to students and graduates of a major clinical discipline:
Psychology, Marriage and Family Therapy,
Social Work, Drug Counseling,
Nursing, Pastoral Counseling, etc.
CEU’s applied for/approval pending.
Many small groups provide MFT or LPC Supervision Hours.

2009-2010 Program
Orientation/Open House
Introduction to Narrative Therapy
Narragrams: Visualizing Narrative Practice for Trauma and Addiction
Narrative Mapping of Preferred Identities and Realities
William Madsen: Collaborative Therapy with Multi-stressed Families
Unstuck! Inviting Struggle, Stress and Conflict Free Couples Therapy
Narrative, Solution-Focused & Collaborative Therapies Today!,
Working Creatively with Families and Children with Art, Sculpture and Music
John Windslade: Narrative Mediation: A New Approach to Conflict Resolution
Narrative Supervision Process and the Self-of-the-Therapist

Note: Final Course Program and Dates to be confirmed. Check below for updates:
Phone: 612-377-9190 x 1
Website: www.kenwoodcenter.org

Main Faculty
Walter H. Bera, PhD, Founder and Director of the Kenwood Therapy Center has been a therapist for 30 years with special interests in the development of clinical theory and
practice, issues of abuse, power and ethics. Walter holds licenses as a LP, LMFT and LPC.
William C Madsen, PhD, is the Director of the Training Program in Collaborative and Narrative Therapies in Cambridge, MA. He is the author of Collaborative Therapy with Multi-stressed Families.
John R. Stillman, LICSW is a graduate of the first International Diplomate Program in Narrative Therapy with Michael White at the Dulwich Centre in Adelaide, Australia and a member of their international faculty and has taught in Bangladesh, India, South Korea and Russia.
John Windslade.is the co-director of the and the author of Narrative Mediation: A New Approach to Conflict Resolution. John teaches at universities in California and New Zealand.

 

Other Items of Interest:

Microsoft in Education Homepage

Adobe in Education Homepage

ZDNet Education Blog (Technology related)

Tangential Items:

 

 
 

 

ADLER GRADUATE SCHOOL
1550 East 78th Street, Richfield, MN 55423
Phone: 612-861-7554
Fax: 612-861-7559
E-mail: info@alfredadler.edu
© 2007 Adler Graduate School
All Rights Reserved